<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04329403</url>
  </required_header>
  <id_info>
    <org_study_id>CR191-18</org_study_id>
    <nct_id>NCT04329403</nct_id>
  </id_info>
  <brief_title>Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled, Parallel Group Design, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Topical Adapalene Gel, 0.1 % in Healthy Males and Nonpregnant Female Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurobindo Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurobindo Pharma Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the therapeutic equivalence of topical Adapalene Gel, 0.1 % and
      Differin®(Adapalene) Gel, 0.1 % in the treatment of acne vulgaris and to demonstrate the
      superiority of the efficacy of the test and reference products over the placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bio-Equivalence study with a clinical endpoint in the treatment of acne vulgaris comparing
      adapalene cream, 0.1% test product versus the reference listed drug (RLD) and placebo
      (vehicle) control, each administered as one application once a day in the evening for 12
      weeks
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Market reasons
  </why_stopped>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change from baseline in the inflammatory lesion count.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean percent change compared to baseline inflammatory lesion count (papules and pustules) at Day 84 in per protocol population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change from baseline in the non-inflammatory lesion count.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean percent change compared to baseline non-inflammatory lesion count (open and closed comedones) at Day 84 in per protocol population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a clinical response as success or failure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Success will be defined as IGA score that is at least 2 grades less than the baseline assessment. Failure is defined as an IGA score that is the same, higher or one grade lower than the baseline assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lesion count</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of subjects who achieved at least 50 % reduction in lesion counts (inflammatory, non-inflammatory and total lesion count)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene Gel, 0.1%, applied as thin film once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Differin® (Adapalene) Gel, 0.1%, applied as thin film once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Gel, 0.1%, applied as thin film once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene 0.1% Gel</intervention_name>
    <description>A thin film of the assigned medication to be applied once daily in the evening for 12 weeks</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Differin 0.1% Topical Gel</intervention_name>
    <description>A thin film of the assigned medication to be applied once daily in the evening for 12 weeks</description>
    <arm_group_label>Reference Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A thin film of the assigned medication to be applied once daily in the evening for 12 weeks</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or nonpregnant, nonlactating female aged ≥ 12 and ≤ 40 years with a clinical
             diagnosis of acne vulgaris

          2. On the face, ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ≥ 20
             inflammatory lesions (i.e., papules and pustules) AND ≤ 2 nodulocystic lesions (i.e.,
             nodules and cysts)

          3. Investigator's Global Assessment (IGA) of acne severity Grade 2, 3, or 4

          4. Willing to refrain from use of all other topical acne medications or antibiotics
             during the 12-week treatment period

          5. If female of childbearing potential, willing to use an acceptable form of birth
             control during the study

        Exclusion Criteria:

          1. Pregnant, breast feeding or planning a pregnancy

          2. Presence of any skin condition that would interfere with the diagnosis or assessment
             of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid
             folliculitis, or bacterial folliculitis)

          3. Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would interfere
             with diagnosis or assessment of acne vulgaris

          4. History of hypersensitivity or allergy to adapalene, retinoids and/or any of the study
             medication ingredients

          5. Use within 6 months prior to baseline or during the study of oral retinoids (e.g.,
             Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day
             (multivitamins are allowed)

          6. Use for less than 3 months prior to baseline of estrogens or oral contraceptives; use
             of such therapy must remain constant throughout the study

          7. Use on the face within 1 month prior to baseline or during the study of 1) cryo
             destruction or chemo destruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne
             surgery, 5) intralesional steroids, or 6) x-ray therapy

          8. Use within 1 month prior to baseline or during the study of 1) systemic steroids, 2)
             systemic antibiotics, 3) systemic treatment for acne vulgaris (other than oral
             retinoids, which require a 6-month washout), or 4) systemic anti-inflammatory agents

          9. Use within 2 weeks prior to baseline or during the study of 1) topical steroids, 2)
             topical retinoids, 3) topical acne treatments including over-the-counter preparations,
             4) topical anti-inflammatory agents, or 5) topical antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

